Endometrial Cancer—From Diagnosis to Management
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 9 April 2025 | Viewed by 21
Special Issue Editors
Interests: reproduction; endometriosis; cancer study
Special Issue Information
Dear Colleagues,
Endometrial cancer (EC) is the sixth most common cancer to affect women worldwide and the most prevalent gynecologic malignancy in American women. Although EC is curable when found and treated early, the 5-year overall survival rate for stage IV EC is only 15–17%. In recent years, EC's incidence and mortality rates have been increasing. According to the American Cancer Society, about 67,880 new cases are expected in 2024, the management of which requires a deeper understanding of the disease pathophysiology and an advanced discovery of strategies for early diagnosis.
In fact, there is currently no standard or routine screening test for EC. Some patients may not experience common signs and symptoms (e.g., abnormal vaginal bleeding), which results in delayed diagnosis. The most commonly used biomarker, CA-125 in blood tests, can produce false negative or positive results. In addition, due to the biological heterogeneity of EC and the diverse characteristics of the patients, management remains challenging, especially for recurrent cancer.
Thus, this Special Issue aims to discuss diagnosis, novel prognosis biomarkers, and recent advancements in disease management. We welcome for submission to this Special Issue original research articles and reviews. Research may include basic, translational, and clinical studies.
We look forward to receiving your contributions.
Dr. Mingxin Shi
Dr. Xiang Zhao
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endometrial cancer
- prognosis
- diagnosis
- novel biomarker
- immunotherapy
- targeted therapy
- prevention
